Septerna, Inc. filed a Form 8-K on November 4, 2026, disclosing that the company selected SEP-204 as a development candidate for Graves' disease and thyroid eye disease (TED) and reported preclinical data at the 2026 American Thyroid Association Annual Meeting.

Key Highlights

  • Development candidate selected: Septerna announced the selection of SEP-204 as a development candidate for Graves' disease and TED.
  • Preclinical data presented: The company reported preclinical data at the 2026 American Thyroid Association Annual Meeting on November 4, 2026.
  • Press release furnished: A press release titled "Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting" was furnished as Exhibit 99.1.
  • Corporate presentation updated: Septerna updated its corporate presentation, furnished as Exhibit 99.2, for use in meetings with investors, analysts, and others.
  • Emerging growth company: The registrant identified itself as an emerging growth company under applicable SEC rules.

Septerna's SEP-204 Candidate Announcement and ATA Meeting Data

According to the filing, Septerna, Inc. (NASDAQ:SEPN) issued a press release on November 4, 2026, announcing the selection of SEP-204 as a development candidate for Graves' disease and thyroid eye disease. The company also disclosed that it presented preclinical data related to this program at the 2026 American Thyroid Association Annual Meeting on the same date. The press release was furnished as Exhibit 99.1 to the Current Report on Form 8-K.

The filing also disclosed that Septerna updated its corporate presentation in November 2026, intended for use in meetings with investors, analysts, and others. That presentation was furnished as Exhibit 99.2. The company disclosed that all information furnished under Item 7.01, including the two exhibits, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934," as stated in the filing.

The 8-K was signed by Jeffrey Finer, M.D., Ph.D., Chief Executive Officer of Septerna, Inc., on November 4, 2026. The company is incorporated in Delaware, maintains its principal executive offices at 250 East Grand Avenue, South San Francisco, California 94080, and its common stock, par value $0.001 per share, is listed on The Nasdaq Stock Market LLC under the trading symbol SEPN.

What Was Disclosed

Septerna filed a Regulation FD disclosure reporting the selection of SEP-204 as a development candidate for Graves' disease and TED, the presentation of preclinical data at a November 2026 industry meeting, and an updated corporate presentation furnished as exhibits.